Persistence of hepatitis B surface antibody and immune memory to hepatitis B vaccine among medical college students in Madinah
Open Access
- 1 November 2018
- journal article
- research article
- Published by King Faisal Specialist Hospital and Research Centre in Annals of Saudi Medicine
- Vol. 38 (6) , 413-419
Abstract
Globally, about 300 million people are infected with hepatitis B virus (HBV). Among the effective approaches to fight HBV infection is immunization. In 1989, an obligatory hepatitis B vaccine program was launched in Saudi Arabia. Assess hepatitis B surface antibody (anti-HBs) levels among the medical students before and after receiving booster doses of HBV vaccine. Cross-sectional. Taibah University. Students born between 1993 and 1995 were recruited in this study from the Occupational Health Clinic. Students were screened for anti-HBs levels using chemiluminescent microparticle immunoassay (CMIA) before and after booster HBV vaccine doses. Anti-HBs levels before and after booster doses. 335. About half of participants (n=164, 49%) had protective anti-HBs levels ( greater than or equal 10 mIU/mL) to the original primary series of HBV vaccine and received no booster doses. The reimaining 171 (51%) participants were at risk of HBV infection since their anti-HBs levels were less than 10 mIU/mL, despite having received the original primary HBV vaccine. The levels of anti-HBs were higher in female than in male students (P less than .001). In addition, female students showed a stronger humoral immune response to the booster vaccine than male students (P less than .001). When participants were given the three boosters, most participants (98.3%) showed anti-HBs levels of greater than or equal 10 mIU/mL. The results also showed a strong correlation between pre-booster and post-booster anti-HBs levels in the greater than or equal 10 mIU/mL group (r2= 0.52, P less than .001) but not in less than 10 mIU/mL group (r2= 0.003, P=.53). A considerable portion of the participants (about 51%) were at risk of HBV infection since their anti-HBs levels were less than 10 mIU/mL. Booster doses significantly trigger memory immune response and this ensured their protection against the virus. Pre-booster anti-HBs level are a good predictive of post-booster anti-HBs levels in greater than or equal 10 mIU/mL group. The sample size was small. Shortage of collaborators. None.Keywords
This publication has 48 references indexed in Scilit:
- Epidemiology of viral hepatitis in Saudi Arabia: Are we off the hook?Saudi Journal of Gastroenterology, 2012
- The Timing of Hepatitis B Virus (HBV) Immunization Relative to Human Immunodeficiency Virus (HIV) Diagnosis and the Risk of HBV Infection Following HIV DiagnosisAmerican Journal of Epidemiology, 2010
- Hepatitis B: The virus and disease #Hepatology, 2009
- Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at BirthThe Pediatric Infectious Disease Journal, 2008
- Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized ApproachGastroenterology, 2008
- A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: A retrospective follow-up survey in the clinical settingScandinavian Journal of Gastroenterology, 2008
- Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: A follow-up study at 15 years☆Vaccine, 2007
- Exploring the Biological Basis of Hepatitis B E Antigen in Hepatitis B Virus InfectionHepatology, 2003
- Long–Term Response to Hepatitis B Vaccination and Response to Booster in Children Born to Mothers With Hepatitis B E AntigenHepatology, 1999
- Immunogenicity of HBV vaccine in healthy Chinese childrenVaccine, 1983